Myelodysplastic Syndrome (MDS)/ CMML

- Intermediate and High Risk
  - Untreated MDS
    - IRB#15619 Phase 1/2 Vadastuximab Tailrine (SGN-CD33A) plus Standard of care chemo in intermediate to high risk MDS
  - Relapsed/Refractory
    - IRB#15953 Phase 2 treatment with SY-1425, a selective Retinoic Acid Receptor Alpha Agonist
    - IRB#16142 Ph1 Oral AG-120 treatment
    - IRB#11076 Phase I with LOR-253
    - IRB#15977 Non Treatment National MDS Study (ECOG/ACRIN)
    - IRB#15993 Study coming soon (relapsed/refractory MDS)

- IDH1

- Chronic Myelomonocytic Leukemia (CMML)
  - IRB#16142 Ph1 Oral AG-120 treatment

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

12/9/2016
www.ohsu.edu/cancer